Identification of a new alanine racemase in Salmonella Enteritidis and its contribution to pathogenesis

Gut Pathogens
Shilpa RayMrutyunjay Suar

Abstract

Non-typhoidal Salmonella (NTS) infections caused primarily by S. Enteritidis and S. Typhimurium particularly in immunocompromised hosts have accounted for a large percentage of fatalities in developed nations. Antibiotics have revolutionized the cure of enteric infections but have also led to the rapid emergence of pathogen resistance. New powerful therapeutics involving metabolic enzymes are expected to be potential targets for combating microbial infections and ensuring effective health management. Therefore, the need for new antimicrobials to fight such health emergencies is paramount. Enteric bacteria successfully evade the gut and colonize their hosts through specialized virulence strategies. An important player, alanine racemase is a key enzyme facilitating bacterial survival. This study aims at understanding the contribution of alanine racemase genes alr, dadX and SEN3897 to Salmonella survival in vitro and in vivo. We have shown SEN3897 to function as a unique alanine racemase in S. Enteritidis which displayed essential alanine racemase activity. Interestingly, the sole presence of this gene in alr dadX double mutant showed a strict dependence on d-alanine supplementation both in vitro and in vivo. However, Alr compleme...Continue Reading

References

Mar 1, 1983·Journal of Bacteriology·S A WassermanD Botstein
May 16, 1996·The New England Journal of Medicine·T W HennessyM T Osterholm
Mar 1, 1996·Nature Medicine·I GuleriaB R Bloom
Jun 1, 1996·Infection and Immunity·R M CrawfordD L Hoover
Jun 1, 1997·Journal of Bacteriology·P HolsJ Delcour
Feb 7, 1998·Infection and Immunity·A CersiniM L Bernardini
Jul 10, 1999·Clinical Microbiology Reviews·K H Darwin, V L Miller
Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·K A Datsenko, B L Wanner
Jun 9, 2000·Molecular Microbiology·M Hensel
Jun 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·E A Miao, S I Miller
Sep 8, 2000·Current Microbiology·U StrychM J Benedik
Oct 12, 2000·Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology·K ShibataR Yamada
Mar 27, 2001·FEMS Microbiology Letters·U StrychM J Benedik
Nov 1, 2001·Annual Review of Cell and Developmental Biology·J E Galán
Jan 5, 2002·Microbes and Infection·C P Lostroh, C A Lee
Jul 17, 2003·Cellular Microbiology·Scott R Waterman, David W Holden
Jul 21, 2004·Journal of Computational Chemistry·Eric F PettersenThomas E Ferrin
Jan 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Siegfried HapfelmeierWolf-Dietrich Hardt
Apr 11, 2006·Journal of Leukocyte Biology·Rui Appelberg
Oct 17, 2006·Nature Reviews. Microbiology·Guy R Cornelis
Sep 11, 2007·Journal of Bacteriology·Daniel L MilliganKurt L Krause

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
chips
X-ray
Assay
electrophoresis

Software Mentioned

BLAST
CastP
Chimera
BLASTP
Tasser

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.